OmniAb(NASDAQ) OABIW

Market CapN/A

Since IPO (2021)-86%

5 YearN/A

1 Year-72%

1 Month-28%

$0.09

-16.57%

-0.02Today

OmniAb last closing stock price
Metric	Price	Date
Last close	USD 0.08	2026-07-23

OmniAb stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.98%	USD 0.08	2026-07-16
1 month	-27.78%	USD 0.11	2026-06-22
3 month	-18.67%	USD 0.10	2026-04-24
Year to date	-33.86%	USD 0.12	2025-12-31
1 year	-71.68%	USD 0.28	2025-07-23
3 year	-91.82%	USD 0.97	2023-07-24
Since inception	-85.58%	USD 0.55	2021-09-30

OmniAb Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$28.91M

Net Income (TTM)

-$54.28M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$0.09

Volume

Open

$0.09

Price

$0.09

Volume

Open

$0.09

Previous Close

$0.09

Daily Range

$0.09 - $0.09

52-Week Range

$0.05 - $0.29

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$0.09

Volume

Open

$0.09

Previous Close

$0.09

Daily Range

$0.09 - $0.09

52-Week Range

$0.05 - $0.29

Estimated Earnings Date

Aug 6, 2026

OABIW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OmniAb

OmniAb, Inc. is a biotechnology firm based in Emeryville, California, specializing in innovative technologies for therapeutic antibody discovery. Established in 2012, the company offers a unique OmniAb platform that enables partners to access a diverse range of antibody repertoires and advanced screening techniques.

Products and Services

OmniAb platform for therapeutic antibody discovery
Proprietary transgenic animals: OmniRat, OmniChicken, and OmniMouse
Specialized models: OmniFlic and OmniClic for bispecific antibodies

Growth Outlook

Recent quarterly revenue of $14.4 million shows significant growth potential
Strong cash position with $29 million in cash and equivalents
Proprietary technology positions the company for future collaborations

Financial Highlights

Trailing twelve months (TTM) revenue of $41.5 million indicates upward momentum
Current ratio of 4.8 suggests strong liquidity and financial health
Net income for Q1 2026 was -$7.7 million, reflecting ongoing investment in R&D

OmniAb, Inc. is positioned at the forefront of biotechnology, leveraging its proprietary technologies to facilitate the development of next-generation therapeutic agents. The company's innovative platform and specialized animal models provide a competitive edge in the rapidly evolving biopharmaceutical landscape. Recent financial performance highlights a robust revenue trajectory, with a significant increase in quarterly revenue, underscoring the potential for future growth. The strong liquidity position further enhances the company's ability to invest in research and development, paving the way for strategic partnerships and collaborations. As the demand for advanced therapeutic solutions continues to rise, OmniAb's unique offerings may attract interest from various industry players, making it a noteworthy entity in the biotechnology sector.

AI Generated • Jul 12, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Headquarters

EmeryVille, CA 94608, US

OABIW Financials

Key Financial Metrics (TTM)

Gross Margin

35.45%

Operating Margin

-200.35%

Net Income Margin

-187.74%

Return on Equity

-20.31%

Return on Capital

-24.89%

Return on Assets

-18.48%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

Avg. Volume

3.17K

Financials (TTM)

Gross Profit

$10.25M

Operating Income

-$57.93M

EBITDA

-$33.82M

Operating Cash Flow

-$25.50M

Capital Expenditure

-$523.00K

Free Cash Flow

-$26.02M

Cash & ST Invst.

$49.07M

Total Debt

$19.67M

OmniAb Performance Analysis

OmniAb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-6.2%
Q3	2025-09-30	-42.5%
Q4	2025-12-31	274.1%
Q1	2026-03-31	71.9%

OmniAb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	11.8%
Q3	2025-09-30	6.7%
Q4	2025-12-31	21.4%
Q1	2026-03-31	45.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$14.40M

+246.7%

Gross Profit

$8.40M

+102.2%

Gross Margin

58.33%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$7.70M

+57.7%

EBITDA

-$1.70M

+87.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$49.07M

+12.6%

Total Debt

$19.67M

-12.5%

Accounts Receivable

$12.64M

+95.1%

Inventory

$0.00

N/A

Long Term Debt

$15.73M

-15.7%

Short Term Debt

$3.94M

+3.3%

Return on Assets

-18.48%

N/A

Return on Invested Capital

-20.68%

N/A

Free Cash Flow

-$5.08M

+68.4%

Operating Cash Flow

-$4.91M

+69.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CHRSCoherus Oncology, Inc.

CHRSCoherus Oncology, Inc.$1.46+3.55%

CGENCompugen Ltd.

CGENCompugen Ltd.$2.38+4.39%

GNLXGenelux Corporation

GNLXGenelux Corporation$2.95+2.08%

VORVor Biopharma Inc.

VORVor Biopharma Inc.$19.44+0.93%

NTHINeonc Technologies Holdings, Inc.

NTHINeonc Technologies Holdings, Inc.$3.44+0.29%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$3.82+2.14%

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$0.61-0.25%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.88+0.03%

Questions About OABIW

What is the current price of OmniAb?

OmniAb is trading at $0.09 per share.

What is the 52-week range for OmniAb?

Over the past 52 weeks, OmniAb has traded between $0.05 and $0.29.

How much debt does OmniAb have?

OmniAb total debt is unavailable.

How much cash does OmniAb have on hand?

OmniAb does not have cash on hand data available.

What is OmniAb’s dividend yield?

OmniAb does not currently have a dividend yield.

OmniAb(NASDAQ) OABIW

OmniAb Financials at a Glance

OABIW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About OmniAb

OABIW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

OmniAb Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OABIW

What is the current price of OmniAb?

What is the 52-week range for OmniAb?

How much debt does OmniAb have?

How much cash does OmniAb have on hand?

What is OmniAb’s dividend yield?

Premium Investing Services